Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Strategies for Management of the Early Chronic Obstructive Lung Disease

  • Lee, Jung Yeon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University Chungju Hospital) ;
  • Rhee, Chin Kook (Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jung, Ki Suck (Division of Pulmonary Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Yoo, Kwang Ha (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine)
  • Received : 2015.12.09
  • Accepted : 2016.01.06
  • Published : 2016.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Lung function reportedly declines with age and that this decline is accelerated during disease progression. However, a recent study showed that the decline might peak in the mild and moderate stage. The prognosis of chronic obstructive pulmonary disease (COPD) can be improved if the disease is diagnosed in its early stages, prior to the peak of decline in lung function. This article reviews recent studies on early COPD and the possibility of applying the U.S. Preventive Services Task Force recommendation 2008 and 2015 for early detection of COPD in Korea.

Keywords

References

  1. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65. https://doi.org/10.1111/j.1440-1843.2011.01951.x
  2. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046-51. https://doi.org/10.1136/thx.2008.098483
  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease; 2007.
  4. Decramer M, Miravitlles M, Price D, Roman-Rodriguez M, Llor C, Welte T, et al. New horizons in early stage COPD: improving knowledge, detection and treatment. Respir Med 2011;105:1576-87. https://doi.org/10.1016/j.rmed.2010.12.015
  5. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014;69:805-10. https://doi.org/10.1136/thoraxjnl-2013-204815
  6. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015;3:719-28. https://doi.org/10.1016/S2213-2600(15)00254-4
  7. Centers for Disease Control and Prevention. Policy Development Research Work Report. The development of strategies for the prevention and control of COPD. Atlanta: Centers for Disease Control and Prevention; 2013.
  8. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specified analysis of the fouryear trial of tiotropium (UPLIFT). Respir Med 2010;104:1659-67. https://doi.org/10.1016/j.rmed.2010.07.016
  9. Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, de-Torres JP, Cote C, et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J 2014;44:324-31. https://doi.org/10.1183/09031936.00208613
  10. Katsura H, Kanemaru A, Yamada K, Motegi T, Wakabayashi R, Kida K. Long-term effectiveness of an inpatient pulmonary rehabilitation program for elderly COPD patients: comparison between young-elderly and old-elderly groups. Respirology 2004;9:230-6. https://doi.org/10.1111/j.1440-1843.2004.00561.x
  11. Hwang YI, Kim CH, Kang HR, Shin T, Park SM, Jang SH, et al. Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria. J Korean Med Sci 2009;24:621-6. https://doi.org/10.3346/jkms.2009.24.4.621
  12. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest 2013;143:1395-406. https://doi.org/10.1378/chest.12-1135
  13. Rodriguez-Roisin R, Drakulovic M, Rodriguez DA, Roca J, Barbera JA, Wagner PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol (1985) 2009;106:1902-8. https://doi.org/10.1152/japplphysiol.00085.2009
  14. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483. https://doi.org/10.1371/journal.pone.0037483
  15. Van Remoortel H, Hornikx M, Langer D, Burtin C, Everaerts S, Verhamme P, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:30-8.
  16. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease; 2011.
  17. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8. https://doi.org/10.1136/bmj.1.6077.1645
  18. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:95-9.
  19. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008;17:169-75. https://doi.org/10.3132/pcrj.2008.00037
  20. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59. https://doi.org/10.1186/1465-9921-10-59
  21. van den Boom G, Rutten-van Molken MP, Molema J, Tirimanna PR, van Weel C, van Schayck CP. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. Am J Respir Crit Care Med 2001;164:2057-66. https://doi.org/10.1164/ajrccm.164.11.2003151
  22. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. https://doi.org/10.1001/jama.1994.03520190043033
  23. Pelkonen M, Tukiainen H, Tervahauta M, Notkola IL, Kivela SL, Salorinne Y, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax 2000;55:746-50. https://doi.org/10.1136/thorax.55.9.746
  24. Golmohammadi K, Jacobs P, Sin DD. Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary disease. Lung 2004;182:187-96.
  25. Riario-Sforza GG, Incorvaia C, Paterniti F, Pessina L, Caligiuri R, Pravettoni C, et al. Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: a number needed to treat study. Int J Chron Obstruct Pulmon Dis 2009;4:315-9.
  26. The Korea Academy of Tuberculosis and Respiratory Diseases; COPD Guideline Revision Committee. The COPD guideline in Korea: update in 2014. Seoul: The Korean Academy of Tuberculosis and Respiratory Diseases; 2014.
  27. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148:529-34. https://doi.org/10.7326/0003-4819-148-7-200804010-00212
  28. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600. https://doi.org/10.1136/bmj.39503.582396.25
  29. Guirguis-Blake JM, Senger CA, Webber EM, Mularski R, Whitlock EP. Screening for chronic obstructive pulmonary disease: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2015.
  30. Sichletidis L, Spyratos D, Papaioannou M, Chloros D, Tsiotsios A, Tsagaraki V, et al. A combination of the IPAG questionnaire and PiKo-6(R) flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J 2011;20:184-9. https://doi.org/10.4104/pcrj.2011.00038
  31. Frith P, Crockett A, Beilby J, Marshall D, Attewell R, Ratnanesan A, et al. Simplified COPD screening: validation of the PiKo-6(R) in primary care. Prim Care Respir J 2011;20:190-8. https://doi.org/10.4104/pcrj.2011.00040
  32. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8. https://doi.org/10.1016/S0140-6736(09)61298-8
  33. Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 ${\geq}60$% participating in the UPLIFT(R) trial. COPD 2012;9:289-96. https://doi.org/10.3109/15412555.2012.656211
  34. van Dijk WD, Gupta N, Tan WC, Bourbeau J. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD 2014;11:113-20. https://doi.org/10.3109/15412555.2013.781996
  35. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-9. https://doi.org/10.1001/archinte.160.11.1683

Cited by

  1. Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims vol.80, pp.3, 2017, https://doi.org/10.4046/trd.2017.80.3.241
  2. A cluster analysis of chronic obstructive pulmonary disease in dusty areas cohort identified three subgroups vol.17, pp.None, 2016, https://doi.org/10.1186/s12890-017-0553-9
  3. The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey vol.197, pp.3, 2019, https://doi.org/10.1007/s00408-019-00208-5
  4. Reducing chronic obstructive pulmonary disease mortality in Korea: early diagnosis matters vol.34, pp.6, 2016, https://doi.org/10.3904/kjim.2019.327
  5. Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD) vol.9, pp.11, 2016, https://doi.org/10.3390/jcm9113426